PLRX — PLIANT THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746473 ·
Last close
$1.12
Market Cap
$69.35M
52W High
$1.38
52W Low
$1.11
ADV30
487,766
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,772,000 | -20,040,000 | 202,596,000 | 22,190,000 | 37,430,000 |
| Dec 2025 | 0 | — | -23,577,000 | -23,577,000 | 225,228,000 | 45,445,000 | 44,023,000 |
| Sep 2025 | 0 | — | -28,269,000 | -26,301,000 | 276,600,000 | 93,732,000 | 76,294,000 |
| Jun 2025 | 0 | — | -45,592,000 | -43,300,000 | 299,824,000 | 86,820,000 | 79,742,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-98,701,000
Investing CF
$61,076,000
Financing CF
$-32,121,000
CapEx
$-1,479,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-859,396,000
Inventory
—
Receivables
$823,000
ST Investments
$145,499,000
EBIT TTM
$-146,785,000
Pretax Income TTM
$-149,344,000
Interest Exp TTM
$2,559,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -156,373,000 | -149,344,000 | 225,228,000 | 44,023,000 | — | -128,336,000 |
| Dec 2024 | 0 | -228,365,000 | -210,304,000 | 396,949,000 | 92,868,000 | — | -155,503,000 |
| Dec 2023 | 1,580,000 | -184,145,000 | -161,336,000 | 512,154,000 | 38,578,000 | — | -116,361,000 |
| Dec 2022 | 9,685,000 | -127,200,000 | -123,321,000 | 350,613,000 | 37,271,000 | — | -94,631,000 |
TTM Snapshot
Revenues TTM
$-120,936,000
NetIncome TTM
$-156,910,000
OpCashFlow TTM
$0
Assets (Latest)
$396,949,000
Forward EPS
$-0.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XBIT | XBiotech Inc. | $69.82M | $2.29 | — |
| MNOV | MEDICINOVA INC | $68.42M | $1.39 | — |
| EDSA | Edesa Biotech, Inc. | $67.53M | $7.01 | — |
| HYFT | MindWalk Holdings Corp. | $66.80M | $1.43 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $66.59M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-11 20:05 · Yahoo
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2026-05-06 12:30 · Yahoo
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
2026-04-30 12:30 · Yahoo
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
2026-04-18 17:31 · Yahoo
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
2026-03-18 13:00 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
2026-03-11 20:05 · Yahoo
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference
2026-03-01 15:39 · Yahoo
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
2026-02-23 13:00 · Yahoo
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
2025-12-04 12:30 · Yahoo
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
2025-12-01 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.